Evidence map›Paper›PMID 34642411›Full record

ArticleScientific reports2021

Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals.

Anuradha Rajamanickam, Nathella Pavan Kumar, Arul Nancy Pandiarajan, Nandhini Selvaraj, Saravanan Munisankar, Rachel Mariam Renji, Vijayalakshmi Venkatramani, Manoj Murhekar, Jeromie W V Thangaraj, Muthusamy Santhosh Kumar and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Induction of dysfunctional CD14Frontiers in immunology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anuradha Rajamanickam *International Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India. anuradha@nirt.res.in.
Nathella Pavan Kumar *Immunology-ICMR-National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Arul Nancy PandiarajanInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Nandhini SelvarajInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Saravanan MunisankarInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Rachel Mariam RenjiInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Vijayalakshmi VenkatramaniInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.
Manoj MurhekarICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
Jeromie W V ThangarajICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
Muthusamy Santhosh KumarICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
C P Girish KumarICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
Tarun BhatnagarICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
Manickam PonnaiahICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
R SabarinathanICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
V SaravanakumarICMR-National Institute of Epidemiology, Chennai, TamilNadu, India.
Subash BabuInternational Center for Excellence in Research - ICMR- National Institute for Research in Tuberculosis, Chennai, TamilNadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monocytes are thought to play an important role in host defence and pathogenesis of COVID-19. However, a comprehensive examination of monocyte numbers and function has not been performed longitudinally in acute and convalescent COVID-19. We examined the absolute counts of monocytes, the frequency of monocyte subsets, the plasma levels of monocyte activation markers using flowcytometry and ELISA in seven groups of COVID-19 individuals, classified based on days since RT-PCR confirmation of SARS-CoV2 infection. Our data shows that the absolute counts of total monocytes and the frequencies of intermediate and non-classical monocytes increases from Days 15-30 to Days 61-90 and plateau thereafter. In contrast, the frequency of classical monocytes decreases from Days 15-30 till Days 121-150. The plasma levels of sCD14, CRP, sCD163 and sTissue Factor (sTF)-all decrease from Days 15-30 till Days 151-180. COVID-19 patients with severe disease exhibit higher levels of monocyte counts and higher frequencies of classical monocytes and lower frequencies of intermediate and non-classical monocytes and elevated plasma levels of sCD14, CRP, sCD163 and sTF in comparison with mild disease. Thus, our study provides evidence of dynamic alterations in monocyte counts, subset frequencies and activation status in acute and convalescent COVID-19 individuals.

Indexed as

MonocytesAcute DiseaseAdolescentAdultAgedBiomarkersConvalescenceCOVID-19FemaleHumansLeukocyte CountMaleMiddle AgedYoung AdultBiomarkers

Identifiers

PMID34642411
PMCPMC8511073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.